In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Multiple sclerosis occurs when the body ...

Some cancers occurred more frequently in people with multiple sclerosis (MS) than in others, a retrospective study in France ...

The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with ...

High-efficacy therapy was defined as ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri). At ages 23-27, those who had earlier treatment had less disability, said Sifat Sharmin ...

An overhaul of the way Pharmac decides to fund drugs for people with chronic long term diseases is needed, say health economists, who are asking the agency to consider the wider societal burden of the ...

The medicine, called ocrelizumab, is normally given as an infusion through a vein - a process that can take up to four hours in hospital. The new way to give the drug will help free up patients ...

Hacohen reported on a UK cohort of children with MS treated with ocrelizumab, with 66 patients having more than 12 months of follow-up. Of these, only four patients had relapses, and there was no ...

FDA Approves First Injectable for Relapsing and Progressive MSThe FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive ...

About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...

About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...